Effects of Intraportal Pirarubicin on Liver Metastases
Author Information
Author(s): L.H. Ramirez, J.-N. Munck, C. Bognel, Z. Zhao, P. Ardouin, M.-F. Poupon, A. Gouyettes, P. Rougier
Primary Institution: Institut Gustave-Roussy
Hypothesis
Intraportal administration of pirarubicin can achieve enhanced drug concentrations in tumor cells and be effective as adjuvant therapy after colorectal carcinoma resection.
Conclusion
Intraportal pirarubicin is well tolerated and more effective than intravenous administration in preventing extrahepatic dissemination of tumors.
Supporting Evidence
- Portal infusions led to no hematological or hepatic toxicity.
- The mean number of tumor foci was significantly lower in the intraportal group compared to controls.
- The percentage of rabbits with lung metastasis was significantly lower in the intraportal group.
Takeaway
This study tested a new way to give a cancer drug directly to the liver, which worked better than giving it through a vein.
Methodology
24 rabbits were randomized into three groups to receive either no treatment, intravenous pirarubicin, or intraportal pirarubicin, and were analyzed for tumor growth and metastasis.
Limitations
The study was conducted on a small animal model, which may not fully represent human responses.
Participant Demographics
Female New Zealand white rabbits weighing 2.7-3.2 kg.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% C.I.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website